Chimeric Antibody

A recombinant or genetically engineered antibody—e.g., a mouse monoclonal—which contains polypeptides or domains from a different species—e.g., humans—often introduced to reduce the antibody’s immunogenicity
Mentioned in ?
References in periodicals archive ?
Researchers at Hokkaido University in Japan developed a chimeric antibody, using rats, that induces tumor regression in canine malignant cancer.
In this report, we used the unique bioengineering technology of silkworms and established a chimeric antibody (CH-CSLEX-1) with a human IgG constant region and the original binding site of the CSLEX-1 mouse IgM monoclonal antibody.
Unituxin (dinutuximab) is a monoclonal chimeric antibody composed of murine variable heavy and light chain regions and the human constant region for the heavy chain kappa.
Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.
Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice.
Expression of chimeric antibody in mammalian cells using dicistronic expression vector.
The product is a monoclonal chimeric antibody developed to treat neuroblastoma, a malignant tumor developing from nerve tissue and most common in children below five years.
Like infliximab, rituximab is a chimeric antibody, although there was no suggestion in this trial that the additive benefit of MTX was attributable to a reduction in the development of anti-chimeric antibodies, as this protocol did not examine repeat dosing.
The mouse - human chimeric antibody Rituximab has been used in aggressive B-cell lymphomas which express CD20.
The chimeric antibody cetuximab contains a higher proportion of mouse protein and thus is associated with a higher incidence of hypersensitivity reactions.
The twist is adalimumab's convenience and safety profile- adalimumab can be administered subcutaneously every other week and is a humanized antibody; infliximab is given intravenously every 2 months and is a mouse-human chimeric antibody that prompts an immune response in some patients.
The patent includes claims to amino acid sequences and the DNA sequences encoding them in the epratuzumab antibody, either as a humanized antibody or as a chimeric antibody developed by the company.